NEOS Investment Management LLC Reduces Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

NEOS Investment Management LLC reduced its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 18.2% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 127,826 shares of the company’s stock after selling 28,388 shares during the period. NEOS Investment Management LLC’s holdings in Intellia Therapeutics were worth $1,490,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of the company. Whipplewood Advisors LLC bought a new position in shares of Intellia Therapeutics during the 4th quarter worth $40,000. Jones Financial Companies Lllp boosted its position in Intellia Therapeutics by 140.9% during the fourth quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company’s stock worth $45,000 after purchasing an additional 2,280 shares during the period. Daiwa Securities Group Inc. increased its stake in shares of Intellia Therapeutics by 80.6% in the fourth quarter. Daiwa Securities Group Inc. now owns 5,151 shares of the company’s stock worth $60,000 after purchasing an additional 2,299 shares in the last quarter. KBC Group NV raised its position in shares of Intellia Therapeutics by 62.4% in the fourth quarter. KBC Group NV now owns 6,093 shares of the company’s stock valued at $71,000 after purchasing an additional 2,340 shares during the period. Finally, AdvisorNet Financial Inc lifted its stake in shares of Intellia Therapeutics by 96.4% during the 4th quarter. AdvisorNet Financial Inc now owns 10,085 shares of the company’s stock valued at $118,000 after buying an additional 4,950 shares in the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently weighed in on NTLA shares. Chardan Capital reduced their price objective on shares of Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating for the company in a research note on Friday, February 28th. HC Wainwright assumed coverage on Intellia Therapeutics in a research note on Wednesday, March 5th. They set a “buy” rating and a $30.00 price objective on the stock. JPMorgan Chase & Co. restated a “neutral” rating and issued a $13.00 target price (down previously from $45.00) on shares of Intellia Therapeutics in a research note on Friday, February 28th. Morgan Stanley downgraded shares of Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $56.00 to $11.00 in a report on Monday, January 27th. Finally, StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a research report on Monday, March 3rd. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $37.56.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the company’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the sale, the chief executive officer now directly owns 941,115 shares in the company, valued at $11,462,780.70. This represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In the last 90 days, insiders have sold 29,000 shares of company stock valued at $352,551. Insiders own 3.20% of the company’s stock.

Intellia Therapeutics Price Performance

Shares of NASDAQ NTLA opened at $8.07 on Friday. The stock has a market capitalization of $835.38 million, a P/E ratio of -1.48 and a beta of 1.97. Intellia Therapeutics, Inc. has a one year low of $8.03 and a one year high of $28.18. The firm’s 50 day simple moving average is $9.98 and its two-hundred day simple moving average is $13.77.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.